{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-24-000521","form_type":"8-K","ticker":"PTHS","cik":"0001919246","company_name":"Pelthos Therapeutics Inc.","filed_at":"2024-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.310962+00:00","generated_at":"2026-06-04T22:35:12.501470+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Chromocell presents pipeline update at Sidoti conference, plans Phase 2a for CC8464","bullets":["Phase 1 of CC8464 completed; 6 of 159 subjects (4%) experienced a rash; FDA accepted dose-escalation plan to reduce incidence.","Plans Phase 2a proof-of-concept in idiopathic small fiber neuropathy (~240 patients) and open-label erythromelalgia study (N=10).","Eye pain program: developing a CC8464 eye drop; pre-clinical ophthalmologic safety studies and POC in PRK surgery patients planned.","Sublingual programs: exclusive worldwide license from Benuvia for diclofenac, rizatriptan, ondansetron; 505(b)(2) regulatory pathway.","Company presented at Sidoti Small Cap Conference on March 13, 2024, with CEO Frank Knuettel and CMO Eric Lang."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-24-000521","json":"https://secwatch.observer/filing/0001753926-24-000521.json","markdown":"https://secwatch.observer/filing/0001753926-24-000521.md","text":"https://secwatch.observer/filing/0001753926-24-000521.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1919246/000175392624000521/0001753926-24-000521-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1919246/000175392624000521/g084118_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T22:35:12.501470+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}